RCAG
TXG icon

Rehmann Capital Advisory Group’s 10x Genomics TXG Stock Holding History

Rehmann Capital Advisory Group’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-3,856
Closed -$498K – 587
2021
Q3 		$498K Buy
+3,856
New +$662K 0.05% 317
2021
Q1 		– Sell
-1,781
Closed -$252K – 530
2020
Q4 		$252K Buy
+1,781
New +$258K 0.03% 414

Other funds holding TXG

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Rehmann Capital Advisory Group's TXG Position: Q4 2021 in Review

Rehmann Capital Advisory Group sold out of 10x Genomics (TXG) in Q4 2021, closing a stake of 3,856 shares — an estimated $498K sold.

Rehmann Capital Advisory Group first reported a position in TXG in Q4 2020 and held it in 2 quarters. The position peaked at $498K in Q3 2021. 365 funds tracked by Wall St. Rank hold TXG as of Q4 2021.

  • Rehmann Capital Advisory Group reported no remaining 10x Genomics position as of Q4 2021 after selling out during the quarter.
  • Rehmann Capital Advisory Group sold 3,856 10x Genomics shares in Q4 2021, an estimated $498K.
  • Rehmann Capital Advisory Group first reported a position in 10x Genomics in Q4 2020 and held it in 2 quarters.
  • Rehmann Capital Advisory Group's 10x Genomics position peaked at $498K in Q3 2021.
  • 365 funds tracked by Wall St. Rank held 10x Genomics as of Q4 2021.

Based on Rehmann Capital Advisory Group's 13F filing for Q4 2021, filed 2 Mar 2022.